The top 10 medical disruptors of 2018

4. The unprecedented reduction of LDL cholesterol

There is a new class of LDL cholesterol lowering drugs that are expected to be disruptors in the next year. The new drugs are expected to lower cholesterol to unprecedented levels.

When taken with a Statin cholesterol lowering drug, the new class of drugs is expected to lower cholesterol levels by 75%.

The small interfering RNA therapy to lower LDL was also a new innovation in 2017. They are given twice a year instead of monthly or weekly like other treatments.

Dr. Leslie Cho of the Heart & Vascular Institute at the Cleveland Clinic suggests that we will continue to see a new class of agents to lower LDL levels in 2018.

Statin drugs could one day be an over-the-counter drug, said Cho.

Next >>

Engineering Better Devices at DeviceTalks Minnesota DeviceTalks Minnesota's engineering track is designed to provide attendees with with actionable lessons in a peer-to-peer format on topics such as: Human factors engineering Patient-centric device development R&D trends Manufacturing and scalability Navigating the product development process from start to finish "How We Built This" panels with top medical device groups Join industry leaders and medical device professionals at the most awaited medtech conference of the year, DeviceTalks Minnesota. Use code DT15 to save 15%! REGISTER NOW